Austrian Primary Biliary Cholangitis Registry Study
Part of Digestive system clinical trials.
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with primary biliary cholangitis (PBC) confirmed by blood tests, antibodies, or liver biopsy
- Your alkaline phosphatase enzyme level has been consistently elevated for at least 6 months, OR you have specific antibodies in your blood, OR you have characteristic changes on liver biopsy
- You are willing to provide written consent to participate and allow your health information to be included in the registry
- You have not withdrawn your consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.